Cargando…

Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation

OBJECTIVE: To investigate the impact of pulmonary rehabilitation (PR) on functional outcomes and health-related quality of life (HRQoL) in idiopathic pulmonary fibrosis (IPF) patients placed on a lung transplant waitlist and receiving antifibrotic therapy (AFT). METHODS: This was a retrospective obs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Monica Pruss, Branchini, Gisele, Nunes, Fernanda Bordignon, Altmayer, Stephan, Hetzel, Guilherme Moreira, Romero, Iveth, Rubin, Adalberto Sperb, Florian, Juliessa, Nascimento, Douglas Zaione, Watte, Guilherme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970374/ https://www.ncbi.nlm.nih.gov/pubmed/36753211 http://dx.doi.org/10.36416/1806-3756/e20220250

Ejemplares similares

Ambulatory oxygen therapy in lung transplantation candidates with idiopathic pulmonary fibrosis referred for pulmonary rehabilitation
por: Miozzo, Aline Paula, et al.
Publicado: (2023)

Functional improvement in patients with idiopathic pulmonary fibrosis undergoing single lung transplantation
por: Rubin, Adalberto Sperb, et al.
Publicado: (2015)

Long-term survival following unilateral lung transplantation for end-stage silicosis relative to idiopathic pulmonary fibrosis
por: Perin, Fabiola Adélia, et al.
Publicado: (2022)

Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation
por: Florian, Juliessa, et al.
Publicado: (2019)

Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics
por: Hochhegger, Bruno, et al.
Publicado: (2019)

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015)

Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2021)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
por: Kang, Jieun, et al.
Publicado: (2021)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
por: Cottin, Vincent, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

High-resolution CT pulmonary findings in children with severe asthma()
por: Silva, Thiago Krieger Bento da, et al.
Publicado: (2020)

Air trapping in usual interstitial pneumonia pattern at CT: prevalence and prognosis
por: Hochhegger, Bruno, et al.
Publicado: (2018)

Predictors of noncompliance to pulmonary tuberculosis treatment: An insight from South America
por: Madeira de Oliveira, Samanta, et al.
Publicado: (2018)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

High resolution computed tomography patterns in interstitial lung disease (ILD): prevalence and prognosis
por: Almeida, Renata Fragomeni, et al.
Publicado: (2020)

Ultra-low-dose chest computed tomography without anesthesia in the assessment of pediatric pulmonary diseases()
por: Dorneles, Cristina Manera, et al.
Publicado: (2018)

Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
por: Assayag, Deborah
Publicado: (2021)

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
por: Kølner-Augustson, Line, et al.
Publicado: (2020)

A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis
por: Mooney, Joshua, et al.
Publicado: (2021)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
por: Graney, Bridget A, et al.
Publicado: (2018)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
por: Casillo, Valeria, et al.
Publicado: (2019)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment
por: Balestro, Elisabetta, et al.
Publicado: (2019)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study
por: Yang, Cheng-Chun, et al.
Publicado: (2022)

Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
por: Suzuki, Yuzo, et al.
Publicado: (2021)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oduvncu14idvisbiti85vt4oeh